Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Comment: Advances in lung cancer presented at ASCO 2014

Comment: Advances in breast cancer presented at ASCO 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Checkpoint blockade: a concept or already a reality?

Emerging pathways in immunotherapy

Recent advances in mantle cell lymphoma: Expert panel discussion